ADXS - Advaxis Inc Stock Price, Fair Value and News

0.22USD0.00 (0.00%)Market Closed

Market Summary

USD0.220.00

Market Closed

0.00%

ADXS Stock Price

View Fullscreen

ADXS RSI Chart

ADXS Valuation

Market Cap

9.4M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

721.49

EV/EBITDA

-0.24

Price/Free Cashflow

-0.32

ADXS Price/Sales (Trailing)

ADXS Profitability

Operating Margin

-26869.23%

EBT Margin

-399876.92%

Return on Equity

196.88%

Return on Assets

-289.96%

Free Cashflow Yield

-314.52%

ADXS Fundamentals

ADXS Revenue

Revenue (TTM)

13.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ADXS Earnings

Earnings (TTM)

-48.1M

Earnings Growth (Yr)

27.94%

Earnings Growth (Qtr)

-236.19%

Breaking Down ADXS Revenue

Last 7 days

-50%

Last 30 days

-66.1%

Last 90 days

-69.9%

Trailing 12 Months

-56.0%

How does ADXS drawdown profile look like?

ADXS Financial Health

Current Ratio

0.3

Debt/Equity

-0.33

Debt/Cashflow

-3.62

ADXS Investor Care

Shares Dilution (1Y)

793.27%

Diluted EPS (TTM)

-11.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	522.3K	352.5K	182.8K	13.0K
2022	3.0M	2.4M	1.3M	250.0K
2021	3.7M	3.8M	3.8M	3.2M
2020	0	14.0M	7.1M	253.0K
2019	12.0M	15.0M	17.9M	20.9M
2018	10.3M	8.6M	6.7M	6.1M
2017	7.5M	11.0M	14.0M	12.0M
2016	1.3M	250.0K	250.0K	4.0M
2014	0	672.3K	836.2K	1.0M
2010	0	0	269.1K	508.5K
2009	0	0	0	29.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Advaxis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	israel biotech fund i, l.p.	acquired	11,138,900	0.4	27,847,200	-
Feb 07, 2024	israel biotech fund i, l.p.	sold (taxes)	-6,599,580	1.2465	-5,294,490	-
Oct 18, 2023	amoon growth fund limited partnership	sold	-	-	-	-
Oct 18, 2023	israel biotech fund i, l.p.	bought	-	-	1,317,720	-
Jan 19, 2023	sidransky david	acquired	-	-	46.00	-
Mar 13, 2020	appel roni	sold	-1,320	0.55	-2,401	-
Mar 12, 2020	appel roni	sold	-116	0.58	-200	-
Mar 11, 2020	appel roni	sold	-267	0.67	-399	-
Apr 11, 2019	henderson molly	acquired	9,199	3.6799	2,500	executive vice president & cfo
Apr 11, 2019	gutierrez andres	acquired	13,928	3.7142	3,750	executive vice president & cmo

Which funds bought or sold ADXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Vermillion & White Wealth Management Group, LLC	new	-	2.00	2.00	-%

Are Funds Buying or Selling ADXS?

Are funds buying ADXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADXS

No. of Funds

Unveiling Advaxis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	redmile group, llc	1.9%	211,014	SC 13G/A
Feb 12, 2024	schindel yair chaim	1.31%	560,602	SC 13G/A
Feb 12, 2024	israel biotech fund i, l.p.	40.94%	20,661,639	SC 13D/A
Nov 21, 2023	israel biotech fund i, l.p.	68.6%	23,180,561	SC 13D/A
Oct 31, 2023	israel biotech fund i, l.p.	20.9%	2,584,909	SC 13D/A
Oct 23, 2023	schindel yair chaim	5.21%	560,602	SC 13G/A
Sep 11, 2023	israel biotech fund i, l.p.	31.3%	1,925,601	SC 13D
Feb 08, 2023	redmile group, llc	6.8%	332,353	SC 13G
Jan 30, 2023	schindel yair chaim	12.20%	560,602	SC 13G
Feb 16, 2021	cvi investments, inc.	2.1%	2e+06	SC 13G/A

Recent SEC filings of Advaxis Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	15-12G	15-12G
Apr 26, 2024	10-K/A	Annual Report
Apr 19, 2024	8-K/A	Current Report
Apr 16, 2024	10-K	Annual Report
Apr 15, 2024	S-8 POS	Employee Benefits Plan
Apr 15, 2024	S-8 POS	Employee Benefits Plan
Apr 15, 2024	S-8 POS	Employee Benefits Plan
Apr 15, 2024	S-8 POS	Employee Benefits Plan
Apr 15, 2024	S-8 POS	Employee Benefits Plan
Apr 15, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to Advaxis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Advaxis Inc News

Latest updates

Advaxis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q3	2022Q2	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2
Revenue	-100.0%	-	4,500	9,000	29,500	50,000	70,500	91,000	64,500	38,000	250,000	500,000	717,500	935,000	625,000	250,000	1,375,000	1,615,000	807,500	-	333	666
Cost Of Revenue	-	-	-	-	-	-	-	91,000	-	-	-	-	-	-	625,000	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	90,000	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	4,853,000	-	7,291,000	-	3,252,000	-	-	4,371,500	-	4,381,000	7,696,000	5,578,000	-	6,400,000	5,842,000	6,571,000
S&GA Expenses	132.7%	3,370,000	1,448,000	2,763,000	4,604,000	-	1,495,000	2,881,000	2,053,000	2,272,000	1,768,000	2,433,000	-	3,831,500	2,198,000	2,678,000	3,352,000	3,008,000	-	3,027,000	2,384,000	2,649,000
R&D Expenses	-4.8%	5,410,000	5,683,000	5,723,000	7,265,000	-	-10,031,000	7,199,000	2,233,000	5,580,000	1,484,000	7,503,000	-	-7,352,500	7,368,000	1,703,000	4,344,000	2,570,000	-	3,373,000	3,458,000	3,922,000
EBITDA Margin	-1847.3%	-3,970	-203	-105	-71.35	-53.85	-51.40	-34.31	-20.13	-10.80	-16.24	-13.26	-11.21	-3.65	-5.60	-7.72	-	-	-	-	-	-
Income Taxes	58.5%	103,000	65,000	127,000	-4,207,000	-	-459,000	106,000	-383,500	214,000	50,000	189,000	-	-527,000	167,000	-50,000	-	-	-	-100,000	-	50,000
Earnings Before Taxes	-237.8%	-24,570,000	-7,274,000	-8,572,000	-11,568,000	-	12,027,500	-10,079,000	-6,963,000	-7,894,000	-2,390,000	-9,764,000	-	6,012,000	-9,629,000	-3,284,000	-5,107,000	-3,977,000	-	-6,460,000	-5,829,000	-6,273,000
EBT Margin	-1852.4%	-3,998	-204	-106	-71.67	-54.09	-51.63	-34.47	-20.23	-10.87	-16.31	-13.32	-11.26	-3.77	-5.69	-7.77	-	-	-	-	-	-
Net Income	-236.2%	-24,673,000	-7,339,000	-8,699,000	-7,361,000	-	12,392,000	-10,185,000	-6,963,000	-8,108,000	-2,440,000	-9,953,000	-	6,359,000	-9,796,000	-3,334,000	-5,107,000	-3,977,000	-	-6,460,000	-5,829,000	-6,323,000
Net Income Margin	-1677.8%	-3,697	-208	-107	-72.79	-54.93	-51.46	-34.94	-20.57	-11.11	-16.63	-13.58	-11.48	-3.73	-5.75	-7.88	-	-	-	-	-	-
Free Cashflow	-2.9%	-7,200,000	-6,998,000	-8,602,000	-6,700,000	11,058,000	11,058,000	4,700,000	4,700,000	1,528,000	1,528,000	-9,984,000	15,125,000	15,125,000	-2,803,000	-2,803,000	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	137.5%	16,579	6,981	12,151	20,995	7,769	25,930	14,260	30,101	37,518	46,498	41,127	46,780	51,022	55,771	45,947	45,828	38,526	40,019	45,210	51,348	45,257
Current Assets	65.4%	7,528	4,552	9,556	18,261	3,188	25,759	13,032	29,817	34,177	43,116	39,740	43,257	47,442	52,113	35,528	44,240	27,851	27,299	31,768	37,153	36,149
Cash Equivalents	130.0%	4,882	2,123	7,079	16,839	2,408	25,208	11,195	28,200	32,100	36,480	36,982	41,614	45,257	48,110	33,318	42,025	25,178	23,846	28,217	34,156	32,363
Net PPE	-36.1%	540	845	882	950	960	38.00	999	73.00	84.00	100	1,120	118	278	333	2,189	1,283	2,393	3,667	3,893	4,121	4,350
Goodwill	-	4,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-	-	-	-	-	-	2,303	-	1,906	2,367	3,724	-	7,892	6,745	8,220	8,372	-	8,346	8,553	9,773	9,800	5,726
Current Liabilities	193.4%	25,018	8,527	8,427	9,833	6,201	2,303	5,705	1,906	2,367	3,719	6,472	7,880	6,745	8,220	3,577	6,877	3,291	3,249	4,225	4,012	4,521
Long Term Debt	293.7%	8,141	2,068	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	293.7%	8,141	2,068	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-24,417	-	1,009	9,675	-1,099	23,627	8,338	28,195	35,151	38,549	34,158	38,888	44,277	47,551	37,575	38,398	30,180	31,466	35,437	41,548	39,531
Retained Earnings	-14.3%	-197,200	-172,553	-165,214	-156,515	-149,154	-442,959	-139,600	-438,368	-431,405	-428,965	-111,141	-428,600	-423,156	-419,822	-414,715	-70,887	-410,738	-404,278	-398,449	-392,126	-384,269
Additional Paid-In Capital	3.9%	172,797	166,307	166,218	166,185	148,052	466,584	147,586	466,561	466,554	467,368	145,160	467,486	467,287	467,227	452,174	109,157	440,917	435,682	433,826	433,614	423,750
Shares Outstanding	147.6%	11,857	4,788	4,780	4,773	2,639	1,816	2,901	1,816	1,820	1,820	-	1,820	1,544	1,399	-	-	-	-	-	-	-
Float	-	-	-	3,700	-	-	-	-	-	11,864	-	-	-	-	71,183	-	-	-	-	39,995	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q3	2022Q2	2022Q2	2022Q1	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3
Cashflow From Operations	-2.9%	-7,200	-6,998	-8,602	-6,700	-	11,058	-	4,700	-	1,528	-9,984	-4,138	-	15,125	-	-2,803	-6,114	-2,786	-	-3,218	-5,302
Share Based Compensation	-195.5%	-85.00	89.00	33.00	1,186	-	-1,817	-	25.00	1,375	23.00	643	26.00	-	-1,398	1,689	60.00	215	236	-	184	255
Cashflow From Investing	-	-	-	-	-	-	35.00	-	-66.00	-	-77.00	-	-58.00	-	-6.00	-	-50.00	156	-210	-	-327	-63.00
Cashflow From Financing	100.0%	4,000	2,000	-1,200	21,201	-	-1,468	-	-1,000	-	-982	44.00	4,312	-	2,503	-	-	20,750	11,136	-	4,877	994

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADXS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 13	$ 692
Cost of Revenue	(13)	(602)
Gross Profit		90
Research and Development	24,081	27,851
General and Administrative	12,185	9,742
Operating Loss	(36,266)	(37,503)
Financial income (expenses), net	(15,718)	74
Loss before taxes on income	(51,984)	(37,429)
Taxes on Income	3,912	(584)
Net Loss	$ (48,072)	$ (38,013)
Net Loss per Share attributable to Common Stockholders, Basic	$ (7.99)	$ (13.13)
Net Loss per Share attributable to Common Stockholders, Diluted	$ (7.99)	$ (13.13)
Weighted Average Shares Used to Compute Net Loss per Share, Basic	6,019,063	2,895,130
Weighted Average Shares Used to Compute Net Loss per Share, Diluted	6,019,063	2,895,130

ADXS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current Assets:

Cash and Cash Equivalents

$ 4,882

$ 2,408

Trade Receivables

234

Prepaid Expenses and Other Current Assets

2,646

546

Total Current Assets

7,528

3,188

Long-Term Assets:

Deferred issuance costs

1,953

Intangible assets, net

3,898

Goodwill

4,500

Operating lease right of use asset

102

1,462

Property and Equipment, Net

540

960

Other Assets

206

Total Long-Term Assets

9,051

4,581

Total Assets

16,579

7,769

Current Liabilities:

Trade Payables

6,076

4,080

Operating lease liabilities

166

419

Accrued expenses and other payables

5,554

708

Side Agreement and reinvestment rights

^[1]

8,436

Accrued payroll and employee benefits

786

994

Proceed from Asset Sale

4,000

Total Current Liabilities

25,018

6,201

Long-Term Liabilities:

Long-term warrant liability

^[1]

6,057

Convertible Note

^[1]

8,141

Uncertain tax position

1,771

1,335

Long-term operating lease liabilities

1,332

Total Long-Term Liabilities

15,978

2,667

Stockholders’ Equity:

Common Stock of $0.001 par value per share; 170,000,000 and 37,480,000* shares authorized at December 31, 2023 and 2022, respectively; 11,896,845 and 2,695,067* shares issued at December 31, 2023 and 2022, respectively; 11,857,393 and 2,638,663* shares outstanding at December 31, 2023 and 2022, Respectively.

Additional Paid-in Capital

172,797

148,052

Accumulated Deficit

(197,226)

(149,154)

Total Stockholders’ Equity

(24,417)

(1,099)

Total Liabilities and Stockholders’ Equity

$ 16,579

$ 7,769

[1]	Received from related party see note 14.

About Advaxis Inc

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.

CEO	Mr. Kenneth A. Berlin J.D.
WEBSITE	ayalapharma.com
INDUSTRY	Biotechnology

Advaxis Inc Frequently Asked Questions

What is the ticker symbol for Advaxis Inc? What does ADXS stand for in stocks?

ADXS is the stock ticker symbol of Advaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Advaxis Inc (ADXS)?

As of Fri May 17 2024, market cap of Advaxis Inc is 9.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADXS stock?

You can check ADXS's fair value in chart for subscribers.

What is the fair value of ADXS stock?

You can check ADXS's fair value in chart for subscribers. The fair value of Advaxis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Advaxis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Advaxis Inc a good stock to buy?

The fair value guage provides a quick view whether ADXS is over valued or under valued. Whether Advaxis Inc is cheap or expensive depends on the assumptions which impact Advaxis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADXS.

What is Advaxis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ADXS's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 721.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Advaxis Inc's stock?

In the past 10 years, Advaxis Inc has provided -0.364 (multiply by 100 for percentage) rate of return.